文献速递基础与转化研究临床试验与 GCP

同种异体脐带来源间充质干基质细胞治疗膝骨关节炎的作用机制:药理学临床研究方案

Mechanisms of treatment effects using allogeneic, umbilical cord-derived mesenchymal stromal stem cells (MSCs) in knee osteoarthritis: a pharmacological clinical study protocol.
PubMed 文献 · Trials · 2024-08-13

这是一项随机、开放标签临床试验方案,拟纳入20例膝骨关节炎患者,干预组与对照组各10例,主要探索间充质干基质细胞治疗的分子机制。研究将分析滑液、血液和组织样本中与软骨代谢、炎症、免疫调节和疼痛相关的生物标志物及基因表达,并结合患者报告结局指标和临床评估进行治疗前后比较。该探索性研究旨在从分子层面全面揭示间充质干基质细胞的治疗作用。

要点

  • 随机开放标签试验,拟纳入20例膝骨关节炎患者,干预组和对照组各10例。
  • 主要探索间充质干基质细胞治疗相关的分子机制。
  • 分析滑液、血液和组织中软骨代谢、炎症、免疫调节及疼痛相关标志物与基因表达。

核心结论

  • 这是一项探索性研究,旨在从分子层面全面了解间充质干基质细胞对膝骨关节炎的治疗作用,可能为优化和更有效的间充质干基质细胞治疗铺平道路,并促进新型治疗策略的开发。

研究设计与样本

  • 随机、开放标签临床试验,拟纳入20例患者,干预组10例,对照组10例。
  • 主要关注间充质干基质细胞治疗相关的分子机制。
  • 分析滑液、血液和组织样本中与软骨代谢、炎症、免疫调节和疼痛相关的生物标志物及基因表达。
  • 患者接受治疗前后患者报告结局指标和全面临床评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Knee osteoarthritis (KOA) presents a prevalent orthopedic condition causing substantial impairment in the quality of life and imposing a significant societal and economic burden. Mesenchymal stromal/stem cells (MSCs), known for their regenerative properties and immunomodulatory effects, have emerged as a promising therapeutic avenue in regenerative medicine. Despite MSCs' therapeutic potential, their precise mechanisms of action in KOA remain underexplored. METHODS: Conducted as a randomized, open-label clinical trial, 20 patients will be enrolled, with 10 in the intervention group and 10 in the control group. The primary focus will be to explore the molecular mechanisms associated with MSC therapy. Biomarkers and gene expressions related to cartilage metabolism, inflammation, immune modulation, and pain in the synovial fluid, blood, and tissue samples will be analyzed. Patients will undergo pre- and post-treatment evaluations using patient-reported outcome measures (PROMs) and comprehensive clinical assessments. DISCUSSION: This is an exploratory study with the goal to provide comprehensive insights into the therapeutic effects of MSCs on a molecular level, potentially paving the way for optimized and more effective MSC-based therapies in the management of KOA, as well as furthering the development of novel treatment strategies. TRIAL REGISTRATION: ClinicalTrials.gov, NCT06078059. Registered on 5 October 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Švajger U, Kolar M, Kobold A, et al. Mechanisms of treatment effects using allogeneic, umbilical cord-derived mesenchymal stromal stem cells (MSCs) in knee osteoarthritis: a pharmacological clinical study protocol. Trials. 2024. PMID: 39135209. doi:10.1186/s13063-024-08360-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。